Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

Colorectal cancer (CRC) is a significant cause of morbidity and mortality worldwide. Its early clinical manifestations are often subtle, leading to late-stage diagnosis in about 30% of cases with distant metastases. Liver metastases are widespread and associated with poor prognosis, especially in terms of response to immunotherapy. This prospective study will evaluate the efficacy of combined therapy involving sintilimab, fruquintinib, and radiotherapy in CRC with liver metastases. The primary objectives are to assess progression-free survival, overall survival, and treatment response rates. T

Trial Details

NCT ID
NCT06356584
Phase
PHASE2
Sponsor
Shandong Cancer Hospital and Institute
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Immunotherapy (Sintilimab)
  • Targeted Therapy Agent (Fruquintinib)
  • Radiotherapy (SBRT and LDRT)
Locations (sample)
  • Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

  • ECOG PS 0-2
  • Histologically confirmed colorectal adenocarcinoma with liver metastases (8th edition AJCC)
  • MSS/pMMR subtype
  • Previously received standard first- and second-line systemic anti-tumor therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →